Please email us at Sales@AmericanPharmaWholesale.com with our item No, NDC#,UPC#or best is product link. We are located in Oceanside, California. Search over 100,000 items by Name, Item No., NDC, UPC (without dashes) or by Mfg.Name.
Menu

RX ITEM-Lucemyra- Lofexidine Hydrochloride Tablet Film Coated .18Mg 96 Tab

LUCEMYRA- lofexidine hydrochloride tablet, film coated .18MG 96 TAB 
 NDC Code(s): 27505-050-36, 27505-050-96
 Packager: US WorldMeds, LLC

 Category: HUMAN PRESCRIPTION DRUG LABEL
 DEA Schedule:BRAND: LUCEMYRA NDC: RX27505-0050-96 ,RX27505005096  UPC: 032750-505096,32750505096 LUCEMYRA- lofexidine hydrochloride tablet, film coated .18MG 96 TAB 
 NDC Code(s): 27505-050-36, 27505-050-96
 PacOnly Lic.-Physician,Pharmacy,Dentist,Drug Mfg,Dist.,Gov,Hospital,Lic.Lab,Naturalist,Naturopath,NP,Optometrist,Pharmacist,PA,Physical Therapist,Podiatrist,Research Co.,Uni.,VA,Vet & Wholesalers in scopWant to do Research on this Med or need a large quantity? Email Details with quantity required to:sales@AmericanPharmaWholesale.comVisit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at Retail@Wholesale prices.

RX ITEM-Lucemyra- Lofexidine Hydrochloride Tablet Film Coated .18Mg 96 Tab

$2383.49$2059.00

item No.:RX807740 807740 NDC No. 27505005096 2750505096 27505005096 UPC No.:32750505096 Item No.:27505-0050-96 0-32750-50509-6 032750505096 LUCEMYRA- lofexidine hydrochloride tablet, film coated .18MG 96 TAB
NDC Code(s): 27505-050-36, 27505-050-96
Packager: US WorldMeds, LLC
Category: HUMAN PRESCRIPTION DRUG LABEL
DEA Schedule: None Only Physician,Pharmacy or Licensed Facility can order this Rx Item NDC No.: 27505005096,27505-050-96,2750505096 UPC:32750505096,32750505096

Have a question?

For: Opiate Withdrawal Lucemyra (lofexidine hydrochloride) is a selective alpha 2-adrenergic receptor agonist indicated for reducing the severity of withdrawal symptoms in patients experiencing opioid withdrawal These highlights do not include all the information needed to use LUCEMYRA safely and effectively. See full prescribing information for LUCEMYRA. LUCEMYRA� (lofexidine) tablets, for oral use Initial U.S. Approval: 2018 INDICATIONS AND USAGE LUCEMYRA is a central alpha-2 adrenergic agonist indicated for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults. (1) DOSAGE AND ADMINISTRATION The usual LUCEMYRA dosage is three 0.18 mg tablets taken orally 4 times daily at 5- to 6-hour intervals. LUCEMYRA treatment may be continued for up to 14 days with dosing guided by symptoms. (2.1) Discontinue LUCEMYRA with a gradual dose reduction over 2 to 4 days. (2.1) Hepatic or Renal Impairment: Dosage adjustments are recommended based on degree of impairment. (2.2, 2.3) DOSAGE FORMS AND STRENGTHS Tablets: 0.18 mg. (3) CONTRAINDICATIONS None. (4) WARNINGS AND PRECAUTIONS Risk of Hypotension, Bradycardia, and Syncope: May cause a decrease in blood pressure, a decrease in pulse, and syncope. Monitor vital signs before dosing and advise patients on how to minimize the risk of these cardiovascular effects and manage symptoms, should they occur. Monitor symptoms related to bradycardia and orthostasis. When using in outpatients, ensure that patients are capable of self-monitoring signs and symptoms. Avoid use in patients with severe coronary insufficiency, recent myocardial infarction, cerebrovascular disease, or chronic renal failure, as well as in patients with marked bradycardia. (5.1) Risk of QT Prolongation: LUCEMYRA prolongs the QT interval. Avoid use in patients with congenital long QT syndrome. Monitor ECG in patients with electrolyte abnormalities, congestive heart failure, bradyarrhythmias, hepatic or renal impairment, or in patients taking other medicinal products that lead to QT prolongation. (5.2) Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs: LUCEMYRA potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (5.3) Increased Risk of Opioid Overdose after Opioid Discontinuation: Patients who complete opioid discontinuation are at an increased risk of fatal overdose should they resume opioid use. Use in conjunction with a comprehensive management program for treatment of opioid use disorder and inform patients and caregivers of increased risk of overdose. (5.4) Risk of Discontinuation Symptoms: Instruct patients not to discontinue therapy without consulting their healthcare provider. When discontinuing therapy, reduce dose gradually. (5.5) ADVERSE REACTIONS Most common adverse reactions (incidence ? 10% and notably more frequent than placebo) are orthostatic hypotension, bradycardia, hypotension, dizziness, somnolence, sedation, and dry mouth. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact US WorldMeds at 1-833-LUCEMYRA or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch DRUG INTERACTIONS Methadone: Methadone and LUCEMYRA both prolong the QT interval. ECG monitoring is recommended when used concomitantly. (7.1) Oral Naltrexone: Concomitant use may reduce efficacy of oral naltrexone. (7.2) CYP2D6 Inhibitors: Concomitant use of paroxetine resulted in increased plasma levels of LUCEMYRA. Monitor for symptoms of orthostasis and bradycardia with concomitant use of a CYP2D6 inhibitor. (7.4) See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Revised: 5/2018

LUCEMYRA- lofexidine hydrochloride tablet, film coated .18MG 96 TAB 
 NDC Code(s): 27505-050-36, 27505-050-96
 Packager: US WorldMeds, LLC

 Category: HUMAN PRESCRIPTION DRUG LABEL
 DEA Schedule:
RX ITEM-Lucemyra- Lofexidine Hydrochlori
LUCEMYRA- lofexidine hydrochloride tablet, film coated .18MG 96 TAB NDC Code(s): 27505-050-36, 27505-050-96 Packager: US WorldMeds, LLC Category: HUMAN PRESCRIPTION DRUG LABEL DEA Schedule:

BRAND: LUCEMYRA NDC: RX27505-0050-96 ,RX27505005096  UPC: 032750-505096,32750505096 LUCEMYRA- lofexidine hydrochloride tablet, film coated .18MG 96 TAB 
 NDC Code(s): 27505-050-36, 27505-050-96
 Pac
Lucemyra- Lofexidine Hydrochloride Table
BRAND: LUCEMYRA NDC: RX27505-0050-96 ,RX27505005096 UPC: 032750-505096,32750505096 LUCEMYRA- lofexidine hydrochloride tablet, film coated .18MG 96 TAB NDC Code(s): 27505-050-36, 27505-050-96 Pac

Only Lic.-Physician,Pharmacy,Dentist,Drug Mfg,Dist.,Gov,Hospital,Lic.Lab,Naturalist,Naturopath,NP,Optometrist,Pharmacist,PA,Physical Therapist,Podiatrist,Research Co.,Uni.,VA,Vet & Wholesalers in scop
American Pharma Wholesale
Only Lic.-Physician,Pharmacy,Dentist,Drug Mfg,Dist.,Gov,Hospital,Lic.Lab,Naturalist,Naturopath,NP,Optometrist,Pharmacist,PA,Physical Therapist,Podiatrist,Research Co.,Uni.,VA,Vet & Wholesalers in scop

Want to do Research on this Med or need a large quantity? Email Details with quantity required to:sales@AmericanPharmaWholesale.com
Buy More Save More!
Want to do Research on this Med or need a large quantity? Email Details with quantity required to:sales@AmericanPharmaWholesale.com

Visit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at Retail@Wholesale prices.
AmericanPharmaWholesale.com
Visit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at Retail@Wholesale prices.